FDA authorizes bamlanivimab and etesevimab antibody therapy for post-exposure prophylaxis for COVID |
Clinical News
eMediNexus Coverage from: 
FDA authorizes bamlanivimab and etesevimab antibody therapy for post-exposure prophylaxis for COVID

1 Read Comments                

The US Food and Drug Administration (FDA) revised the emergency use authorization (EUA) for bamlanivimab and etesevimab, given together, to include emergency use as post-exposure prophylaxis for COVID-19 in adults and children, aged >12 years weighing at least 40 kg, who have a high risk for progression to severe disease, including hospitalization or death.Bamlanivimab and etesevimab, given together, are not authorized for use as pre-exposure prophylaxis to prevent COVID-19. The monoclonal an...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now